A randomized controlled trial of pentoxifylline for the prevention of delayed graft function in cadaveric kidney graft.
Ischemia/reperfusion has been implicated in the mechanism of delayed graft function (DGF). Pentoxifylline (PTX) has been shown to suppress TNF alpha (released by activated macrophages, inhibiting subsequent superoxide anion release from neutrophil activation. In addition, PTX decreases cyclosporine (CsA) induced renal endothelial release and vasoconstriction. Thus, administration of PTX to renal transplant patient could be an excellent approach to prevent DGF and vascular toxicity of CsA in the early graft period. One hundred-and-forty consecutive patients receiving cadaveric kidney transplantation were registered in a randomized double-blind study comparing PTX vs. a placebo. PTX had no demonstrable effect on the incidence of DGF, on the rapidity of the renal function recovery, and on the ability to use higher doses of CsA in the first month post-graft.
Noël
C
C
Department of Nephrology, University of Lille, France.
Hazzan
M
M
Coppin
M C
MC
Codaccioni
M X
MX
Pruvot
F R
FR
Labalette
M
M
Lelièvre
G
G
D000328:Adult; D002102:Cadaver; D016572:Cyclosporine / Q000008:administration & dosage / Q000009:adverse effects; D004311:Double-Blind Method; D004730:Endothelium, Vascular / Q000187:drug effects; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects; D015994:Incidence; D007511:Ischemia / Q000517:prevention & control*; D007668:Kidney / Q000098:blood supply / Q000187:drug effects; D016030:Kidney Transplantation / Q000473:pathology / Q000502:physiology*; D008262:Macrophage Activation / Q000187:drug effects; D008264:Macrophages / Q000187:drug effects; D018375:Neutrophil Activation / Q000187:drug effects; D009504:Neutrophils / Q000187:drug effects; D010431:Pentoxifylline / Q000627:therapeutic use*; D010919:Placebos; D015427:Reperfusion Injury / Q000517:prevention & control*; D013481:Superoxides / Q000037:antagonists & inhibitors; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors; D014662:Vasoconstrictor Agents / Q000009:adverse effects; D014665:Vasodilator Agents / Q000627:therapeutic use*
D007166:Immunosuppressive Agents; D010919:Placebos; D014409:Tumor Necrosis Factor-alpha; D014662:Vasoconstrictor Agents; D014665:Vasodilator Agents; D013481:Superoxides; D016572:Cyclosporine; D010431:Pentoxifylline